77 research outputs found
How do galaxies populate haloes in high-density environments? An analysis of the Halo Occupation Distribution in future virialized structures
There are hints suggesting that properties of galaxy populations in dark
matter haloes may depend on their large-scale environment. Recent works point
out that very low-density environments influence halo occupation distribution
(HOD), however there is not a similar analysis focused on high-density
environments. Here we use a simulated set of future virialized superstructures
(FVS) to analyse the occupation of galaxies in haloes within these high
globally dense regions.
We use a publicly available simulated galaxy set constructed with a
semi-analytical model to identify FVS in the simulation. Then, we computed the
HOD within these superstructures for different absolute magnitude thresholds
and make several analysis including the comparison to the global HOD results.
We study the dependence on the results on properties of the FVS such as density
and volume as well as consider the morphology of galaxies. We also analysed the
properties of the stellar content of galaxies and the formation time of the
haloes inside FVS.
We find a significant increase in the HOD inside FVS. This result is present
for all absolute magnitude thresholds explored. The effect is larger in the
densest regions of FVS, but does not depend on the volume of the
superstructure. We also find that the stellar-mass content of galaxies
considerably differs inside the superstructures. Low mass haloes have their
central and satellite galaxies with a higher stellar mass content (50%), and
exhibit mean star ages (20%) older than average. For massive haloes in FVS we
find that only the stellar mass of satellite galaxies varies considerably
corresponding to a decrease of 50%. We find a significant statistical
difference between the formation times of haloes in FVS and the average
population. Haloes residing in superstructures formed earlier, a fact that
leads to several changes in the HOD and their member galaxy properties.Comment: 12 pages, 14 figures, the paper has been accepted to be published by
the A&
Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens
Intralesional administration of cultured dendritic cells (DCs) engineered to produce IL-12 by in vitro infection with recombinant adenovirus frequently displays eradicating efficacy against established subcutaneous tumors derived from the CT26 murine colon carcinoma cell line. The elicited response is mainly mediated by cytolytic T lymphocytes. In order to search for strategies that would enhance the efficacy of the therapeutic procedure against less immunogenic tumors, we moved onto malignancies derived from the inoculation of MC38 colon cancer cells that are less prone to undergo complete regression upon a single intratumoral injection of IL-12-secreting DCs. In this model, we found that repeated injections of such DCs, as opposed to a single injection, achieved better efficacy against both the injected and a distantly implanted tumor; that the use of semiallogeneic DCs that are mismatched in one MHC haplotype with the tumor host showed slightly better efficacy; and that the combination of this treatment with systemic injections of immunostimulatory anti-CD137 (4-1BB) monoclonal antibody achieved potent combined effects that correlated with the antitumor immune response measured in IFN-gamma ELISPOT assays. The elicited systemic immune response eradicates concomitant untreated lesions in most cases. Curative efficacy was also found against some tumors established for 2 weeks when these strategies were used in combination. These are preclinical pieces of evidence to be considered in order to enhance the therapeutic benefit of a strategy that is currently being tested in clinical trials. Supplementary Material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html
Anti-ICAM-2 monoclonal antibody synergizes with intratumor gene transfer of interleukin-12 inhibiting activation-induced T-cell death
PURPOSE:
Systemic treatment with an anti-ICAM-2 monoclonal antibody (mAb; EOL4G8) eradicates certain established mouse tumors through a mechanism dependent on the potentiation of a CTL-mediated response. However, well-established tumors derived from the MC38 colon carcinoma cell line were largely refractory to this treatment as well as to intratumor injection of a recombinant adenovirus encoding interleukin-12 (IL-12; AdCMVIL-12). We sought to design combined therapy strategies with AdCMVIL-12 plus anti-ICAM-2 mAbs and to identify their mechanism of action.
EXPERIMENTAL DESIGN:
Analysis of antitumor and toxic effects were performed with C57BL/6 mice bearing established MC38 tumors. Anti-ovalbumin T-cell receptor transgenic mice and tumors transfected with this antigen were used for in vitro and in vivo studies on activation-induced cell death (AICD) of CD8(+) T cells.
RESULTS:
Combined treatment with various systemic doses of EOL4G8 mAb plus intratumor injection of AdCMVIL-12 induced complete regression of MC38 tumors treated 7 days after implantation. Unfortunately, most of such mice succumbed to a systemic inflammatory syndrome that could be prevented if IFN-gamma activity were neutralized once tumors had been rejected. Importantly, dose reduction of EOL4G8 mAb opened a therapeutic window (complete cure of 9 of 18 cases without toxicity). We also show that ICAM-2 ligation by EOL4G8 mAb on activated CTLs prevents AICD, thus extending IFN-gamma production.
CONCLUSIONS:
Combination of intratumor gene transfer of IL-12and systemic anti-ICAM-2 mAb display synergistic therapeutic and toxic effects. CTL life extension resulting from AICD inhibition by anti-ICAM-2 mAbs is the plausible mechanism of action
Clinical implications of antigen transfer mechanisms from malignant to dendritic cells: Exploiting cross-priming
Expansion and activation of cytolytic T lymphocytes bearing high-affinity T-cell receptors specific for tumor antigens is a major goal of active cancer immunotherapy. Physiologically, T cells receive promitotic and activating signals from endogenous professional antigen-presenting cells (APC) rather than directly from malignant cells. This phenomenon fits with the broader concept of cross-presentation that earlier was demonstrated for minor histocompatibility and viral antigens. Many mechanisms have been found to be capable of transferring antigenic material from malignant cells to APC so that it can be processed and subsequently presented by MHC class I molecules expressed on APC. Dendritic cells (DC) are believed to be the most relevant APC mediating cross-presentation because they can take up antigens from apoptotic, necrotic, and even intact tumor cells. There exist specific molecular mechanisms that ensure this transfer of antigenic material: 1) opsonization of apoptotic bodies; 2) receptors for released heat shock proteins carrying peptides processed intracellularly; 3) Fc receptors that uptake immunocomplexes and immunoglobulins; and 4) pinocytosis. DC have the peculiar capability of reentering the exogenously captured material into the MHC class I pathway. Exploitation of these pieces of knowledge is achieved by providing DC with complex mixtures of tumor antigens ex vivo and by agents and procedures that promote infiltration of malignant tissue by DC. The final outcome of DC cross-presentation could be T-cell activation (cross-priming) but also, and importantly, T-cell tolerance contingent upon the activation/maturation status of DC. Artificial enhancement of tumor antigen cross-presentation and control of the immune-promoting status of the antigen-presenting DC will have important therapeutic implications in the near future
Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies
Immunotherapeutic monoclonal antibodies (mAbs) can be
defined as those that exert their functions by tampering with
immune system cell molecules, causing an enhancement of
antitumor immune responses. Some of these antibodies are
agonistic ligands for surface receptors involved in the activation
of lymphocytes and/or antigen-presenting cells, whereas
others are antagonists of mechanisms that normally limit the
intensity of immune reactions. Several mAbs of this category
have been described to display in vivo antitumor activity in
mouse models. Only anti–CTLA-4 (CD152) mAb has entered
clinical trials, but the preclinical effects described for anti-
CD40, anti-CD137 (4-1BB), anti-CD102 (intercellular adhesion
molecule-2), and regulatory T cell-depleting mAbs should lead
to their prompt clinical development. Their use in combination
with immunizations against tumor antigens has been reported
to be endowed with synergistic properties. This new group of
antitumor agents holds promise for at least additive effects with
conventional therapies of cancer and deserves intensive translational
research
The Gaia-ESO Survey: radial metallicity gradients and age-metallicity relation of stars in the Milky Way disk
We study the relationship between age, metallicity, and alpha-enhancement of
FGK stars in the Galactic disk. The results are based upon the analysis of
high-resolution UVES spectra from the Gaia-ESO large stellar survey. We explore
the limitations of the observed dataset, i.e. the accuracy of stellar
parameters and the selection effects that are caused by the photometric target
preselection. We find that the colour and magnitude cuts in the survey suppress
old metal-rich stars and young metal-poor stars. This suppression may be as
high as 97% in some regions of the age-metallicity relationship. The dataset
consists of 144 stars with a wide range of ages from 0.5 Gyr to 13.5 Gyr,
Galactocentric distances from 6 kpc to 9.5 kpc, and vertical distances from the
plane 0 < |Z| < 1.5 kpc. On this basis, we find that i) the observed
age-metallicity relation is nearly flat in the range of ages between 0 Gyr and
8 Gyr; ii) at ages older than 9 Gyr, we see a decrease in [Fe/H] and a clear
absence of metal-rich stars; this cannot be explained by the survey selection
functions; iii) there is a significant scatter of [Fe/H] at any age; and iv)
[Mg/Fe] increases with age, but the dispersion of [Mg/Fe] at ages > 9 Gyr is
not as small as advocated by some other studies. In agreement with earlier
work, we find that radial abundance gradients change as a function of vertical
distance from the plane. The [Mg/Fe] gradient steepens and becomes negative. In
addition, we show that the inner disk is not only more alpha-rich compared to
the outer disk, but also older, as traced independently by the ages and Mg
abundances of stars.Comment: accepted for publication in A&
Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates
BACKGROUND: Adeno-associated vectors (rAAV) have been used to attain long-term liver gene expression. In humans, the cellular immune response poses a serious obstacle for transgene persistence while neutralizing humoral immunity curtails re-administration. Porphobilinogen deaminase (PBGD) haploinsufficiency (acute intermittent porphyria) benefits from liver gene transfer in mouse models and clinical trials are about to begin. In this study, we sought to study in non-human primates the feasibility of repeated gene-transfer with intravenous administration of rAAV5 vectors under the effects of an intensive immunosuppressive regimen and to analyze its ability to circumvent T-cell immunity and thereby prolong transgene expression.
METHODS: Three female Macaca fascicularis were intravenously injected with 1x1013 genome copies/kg of rAAV5 encoding the human PBGD. Mycophenolate mofetil (MMF), anti-thymocyte immunoglobulin, methylprednisolone, tacrolimus and rituximab were given in combination during 12 weeks to block T- and B-cell mediated adaptive immune responses in two macaques. Immunodeficient and immunocompetent mice were intravenously injected with 5x1012 genome copies/kg of rAAV5-encoding luciferase protein. Forty days later MMF, tacrolimus and rituximab were daily administrated to ascertain whether the immunosuppressants or their metabolites could interfere with transgene expression.
RESULTS: Macaques given a rAAV5 vector encoding human PBGD developed cellular and humoral immunity against viral capsids but not towards the transgene. Anti-AAV humoral responses were attenuated during 12 weeks but intensely rebounded following cessation of the immunosuppressants. Accordingly, subsequent gene transfer with a rAAV5 vector encoding green fluorescent protein was impossible. One macaque showed enhanced PBGD expression 25 weeks after rAAV5-pbgd administration but overexpression had not been detected while the animal was under immunosuppression. As a potential explanation, MMF decreases transgene expression in mouse livers that had been successfully transduced by a rAAV5 several weeks before MMF onset. Such a silencing effect was independent of AAV complementary strand synthesis and requires an adaptive immune system.
CONCLUSIONS: These results indicate that our transient and intensive pharmacological immunosuppression fails to improve AAV5-based liver gene transfer in non-human primates. The reasons include an incomplete restraint of humoral immune responses to viral capsids that interfere with repeated gene transfer in addition to an intriguing MMF-dependent drug-mediated interference with liver transgene expression
Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8
In the course of a clinical trial consisting of intratumoral injections of dendritic cells (DCs) transfected to produce interleukin-12, the use of (111)In-labeled tracing doses of DCs showed that most DCs remained inside tumor tissue, instead of migrating out. In search for factors that could explain this retention, it was found that tumors from patients suffering hepatocellular carcinoma, colorectal or pancreatic cancer were producing IL-8 and that this chemokine attracted monocyte-derived dendritic cells that uniformly express both IL-8 receptors CXCR1 and CXCR2. Accordingly, neutralizing antihuman IL-8 monoclonal antibodies blocked the chemotactic attraction of DCs by recombinant IL-8, as well as by the serum of the patients or culture supernatants of human colorectal carcinomas. In addition, tissue culture supernatants of colon carcinoma cells inhibited DC migration induced by MIP-3beta in an IL-8-dependent fashion. IL-8 production in malignant tissue and the responsiveness of DCs to IL-8 are a likely explanation of the clinical images, which suggest retention of DCs inside human malignant lesions. Impairment of DC migration toward lymphoid tissue could be involved in cancer immune evasion
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.
PURPOSE:
To evaluate the feasibility and safety of intratumoral injection of autologous dendritic cells (DCs) transfected with an adenovirus encoding interleukin-12 genes (AFIL-12) for patients with metastatic gastrointestinal carcinomas. Secondarily, we have evaluated biologic effects and antitumoral activity.
PATIENTS AND METHODS:
Seventeen patients with metastatic pancreatic (n = 3), colorectal (n = 5), or primary liver (n = 9) malignancies entered the study. DCs were generated from CD14+ monocytes from leukapheresis, cultured and transfected with AFIL-12 before administration. Doses from 10 x 10(6) to 50 x 10(6) cells were escalated in three cohorts of patients. Patients received up to three doses at 21-day intervals.
RESULTS:
Fifteen (88%) and 11 of 17 (65%) patients were assessable for toxicity and response, respectively. Intratumoral DC injections were mainly guided by ultrasound. Treatment was well tolerated. The most common side effects were lymphopenia, fever, and malaise. Interferon gamma and interleukin-6 serum concentrations were increased in 15 patients after each treatment, as well as peripheral blood natural killer activity in five patients. DC transfected with AFIL-12 stimulated a potent antibody response against adenoviral capsides. DC treatment induced a marked increase of infiltrating CD8+ T lymphocytes in three of 11 tumor biopsies analyzed. A partial response was observed in one patient with pancreatic carcinoma. Stable disease was observed in two patients and progression in eight patients, with two of the cases fast-progressing during treatment.
CONCLUSION:
Intratumoral injection of DC transfected with an adenovirus encoding interleukin-12 to patients with metastatic gastrointestinal malignancies is feasible and well tolerated. Further studies are necessary to define and increase clinical efficacy
A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis
Surgically resectable synchronic and metachronic liver metastases of colon cancer have high risk of relapse in spite
of standard-of-care neoadjuvant and adjuvant chemotherapy regimens. Dendritic cell vaccines loaded with autologous
tumor lysates were tested for their potential to avoid or delay disease relapses (NCT01348256). Patients with surgically
amenable liver metastasis of colon adenocarcinoma (n = 19) were included and underwent neoadjuvant chemotherapy,
surgery and adjuvant chemotherapy. Fifteen patients with disease-free resection margins were randomized 1:1 to receive
two courses of four daily doses of dendritic cell intradermal vaccinations versus observation. The trial had been originally
designed to include 56 patients but was curtailed due to budgetary restrictions. Follow-up of the patients indicates a
clear tendency to fewer and later relapses in the vaccine arm (median disease free survival –DFS-) 25.26 months, 95% CI 8.
74-n.r) versus observation arm (median DFS 9.53 months, 95% CI 5.32–18.88)
- …